-Reuters
DBV Technologies Receives FDA Feedback On Design Elements For Viaskin Peanut Safety Studies; Expects To Seek Final Alignment With FDA On COMFORT Protocols Prior To Commencing Studies
Received feedback from U.S. Food and Drug Administration (FDA) on DBV's two supplemental safety studies in toddlers (ages 1 – 3 years) and
